Merus N.V., a Dutch clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced that Ono Pharmaceutical (Osaka, Japan) has exercised its option to enter into a new research and license agreement utilizing Merus’ proprietary Biclonics® technology platform to generate a bispecific antibody that binds to a combination of targets designed for the treatment of autoimmune diseases.
In April 2014, Merus and Ono entered into a research and license agreement to jointly develop bispecific antibody therapies for autoimmune diseases. In 2016, Ono selected a lead bispecific antibody candidate that it intends to advance into clinical testing, which triggered a milestone payment to Merus. By exercising its option under the terms of the first agreement, Ono has agreed to fund research activities at Merus that will generate candidate Biclonics® for the new program.
Merus has granted Ono worldwide exclusive rights to develop, manufacture, and commercialize the resulting products developed through the collaboration.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics.
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. It focuses especially on the oncology and diabetes areas.